HOME >> MEDICINE >> NEWS
Zengen reports positive phase I/II trial results of its peptide molecule for vaginal yeast infection

(May 25, 2004) Zengen Inc. announced today positive phase I/II results for its proprietary molecule CZEN-002 for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection. The open label, non-randomized study was designed to evaluate the safety, tolerability and pharmacokinetics of CZEN-002 in patients with VVC.

The majority of subjects in the study reported evidence of efficacy as determined by potassium hydroxide (KOH) tests and mycological cultures - 88.2 percent and 87.5 percent, respectively. A total of 20 female patients with VVC were enrolled and treated in the trial, and 17 completed the study. KOH testing and mycological cultures indicated that CZEN-002 is active and that five days of treatment provided positive evidence of anti-infective efficacy. CZEN-002 appeared safe and well-tolerated with no severe adverse reactions. In 100 percent of the plasma samples evaluated, concentrations of CZEN 002 were either not detected or were below the limit of quantitation.

"This trial clearly established the efficacy of CZEN-002," said William Smith, M.D., F.A.C.C., lead study investigator and associate professor, clinical medicine, at Tulane University School of Medicine and Louisiana State University Medical Center. "The encouraging results provide hope that this compound may become a new treatment option for the millions of women diagnosed each year with VVC."

The primary objective of the study was to evaluate the safety and tolerability of vaginally administered CZEN-002. A secondary objective was to assess the systemic absorption of CZEN-002 as determined by the plasma concentrations of the molecule through 21 days following dosing. The CZEN 002 was delivered to the 20 patients in a vaginal gel specifically designed for the purpose of the study.

"This clinical trial marks a major milestone for Zengen," said James M. Lipton, Ph.D., chief scientific officer of Zengen. "Our peptide appears to
'"/>

Contact: Cattaliya Snider
sniderc@ruderfinn.com
310-479-9929
Zengen
25-May-2004


Page: 1 2 3

Related medicine news :

1. Zengens new study reviews novel approach to control inflammation using melanocortin receptors
2. Lead in the environment causes violent crime, reports University of Pittsburgh researcher at AAAS
3. Study reports women dont experience undue pain, anxiety during mammography screening
4. Risks from labor after prior cesarean delivery low, study reports
5. Federal forum reports Americans aging well, but gaps remain
6. Early reports of thrombosis after insertion of drug-eluting stents
7. Study reports genetic susceptibility to alcoholism in NMDA receptor
8. Parents can provide accurate reports of their childrens ADHD symptoms
9. UCI Tobacco research center reports why teens are most vulnerable to smoking addiction
10. MIT reports new insights in visual recognition
11. Study reports improved method to identify fetal DNA in maternal blood samples

Post Your Comments:
(Date:9/1/2015)... ... September 01, 2015 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... for Lymphoma awareness initiative, the nation’s premier and most high-profile lymphoma awareness campaign. ...
(Date:9/1/2015)... ... September 01, 2015 , ... Philanthropic giving in the U.S. ... issues and needs. Money for Good 2015, released today by Camber Collective, goes to ... annual potential to mobilize up to $22B in new philanthropic giving and shift $25B ...
(Date:9/1/2015)... ... September 01, 2015 , ... Consumers ... American Society for Dermatologic Surgery, according to a new survey that also offers ... on Cosmetic Dermatologic Procedures – which reflects views on cosmetic medical treatments and ...
(Date:9/1/2015)... Fairfax, VA (PRWEB) , ... September 01, 2015 ... ... the Mane Vendor “Hair Extension Vending Machine,” is still strongly maintaining her firm’s ... modern technology, and beauty tools. In her upcoming city-to-city tour, Ellis will be ...
(Date:9/1/2015)... ... ... The Jerry Segal Classic to benefit the patients of Magee Rehabilitation Hospital ... Lafayette Hill, PA. Over the past 26 years, the Classic, organized by the Friends ... to support patients and their families during their time at Magee Rehabilitation Hospital. ...
Breaking Medicine News(10 mins):Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3
(Date:9/1/2015)... Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... the Patent Trial and Appeals Board (PTAB) in response ... filed by a unit of Boston Scientific Corporation, challenging ... 8,359,102 (the ,102 patent). The ,102 patent is one of Nevro,s 55 ...
(Date:9/1/2015)... , Sept. 1, 2015 Ardelyx, ... company focused on gastrointestinal and cardio-renal diseases, today ... of the option and license agreement for Ardelyx,s ... There was no payment associated with termination and ... 2014, Ardelyx and Sanofi entered into an option ...
(Date:9/1/2015)... 1, 2015 NOWDiagnostics Inc., based in Springdale, ... of Canada , a move that ... world where people have greater access to information concerning ... line of unique blood-based rapid tests that allow health ... a variety of ailments and diseases. ZBx Corporation, a ...
Breaking Medicine Technology:Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2Ardelyx Regains NaP2b Program from Sanofi 2Ardelyx Regains NaP2b Program from Sanofi 3NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3
Cached News: